Podcast Pearls
Rationale for NTRK Testing in Patients With Cancer

Download this short summary slideset based on the content from an expert CCO podcast covering TRK biology and oncogenesis, the frequency of NTRK fusions across diverse tumors, and methods for identifying NTRK fusions in the clinic.
George D. Demetri, MD
Alexander Drilon, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 918 KB
Released: October 8, 2021


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bayer HealthCare Pharmaceuticals Inc.

Related Content

Podcast episode with expert insights on new data from SGO 2022 in endometrial, ovarian, and cervical cancers, from Clinical Care Options (CCO)

David Scott Miller, MD, FACOG, FACS Angeles Alvarez Secord, MD, MHSc Released: May 19, 2022

Interactive expert-led video on targeted therapies for glioblastoma, from Clinical Care Options (CCO)

Andrew B. Lassman, MD
Program Director
Timothy Cloughesy, MD Rimas V. Lukas, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: May 19, 2022 Expired: May 18, 2023

Dr Yara Abdou discusses BRCA mutation testing and adjuvant therapy with olaparib in BRCA-mutated, HER2-negative early breast cancer, from Clinical Care Options (CCO)

Yara Abdou, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: May 17, 2022 Expired: May 16, 2023

Slideset from Dr Yara Abdou on adjuvant olaparib in BRCA1/2-mutated, HER2-negative early breast cancer, from Clinical Care Options (CCO)

Yara Abdou, MD Released: May 17, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings